Gene methylation parallelisms between peripheral blood cells and oral mucosa samples in relation to overweight by San-Cristobal R et al.
1 
 
Gene methylation parallelisms between peripheral blood cells 1 
and oral mucosa samples in relation to overweight. 2 
Rodrigo San-Cristobal 1, Santiago Navas-Carretero 1,2, Fermín I. Milagro 1,2,3, J.Ignacio Riezu-Boj 3 
1, 3,  Elizabeth Guruceaga 3, 4, Carlos Celis-Morales 5, Katherine M Livingstone 5, Lorraine 4 
Brennan 6, Julie A. Lovegrove 7, Hannelore Daniel 8, Wim H. Saris 9, Iwonna Traczyk 10, Yannis 5 
Manios 11, Eileen R. Gibney 6, Michael J. Gibney 6, John C. Mathers 5, J. Alfredo Martinez 1,2,3 6 
1 Department of Nutrition, Food Science and Physiology. Centre for Nutrition 7 
Research, University of Navarra, Pamplona, Spain. 8 
2 CIBER Fisiopatología Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, 9 
Madrid, Spain 10 
3 Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 11 
4 Unit of Proteomics, Genomics and Bioinformatics, Center for Applied Medical 12 
Research (CIMA), University of Navarra, Pamplona, Spain. 13 
 5 Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle 14 
University, Campus for Ageing and Vitality, Newcastle Upon Tyne, UK 15 
6 UCD Institute of Food and Health, University College Dublin, Belfield, Dublin 4, 16 
Republic of Ireland  17 
7 Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic 18 
Research, University of Reading, Reading, UK 19 
8 ZIEL Research Center of Nutrition and Food Sciences, Biochemistry Unit, Technische 20 
Universität München, Germany 21 
2 
 
9 Department of Human Biology, NUTRIM, School for Nutrition and Translational 22 
Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands  23 
10 Department of Human Nutrition, Faculty on Health Sciences, Medical University of 24 
Warsaw, Poland. 25 
11 Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.  26 
3 
 
Abstract 27 
Epigenetics has an important role in the regulation of metabolic adaptation to environmental 28 
modifications. In this sense, the determination of epigenetic changes in non-invasive samples 29 
during the development of metabolic diseases could play an important role in the procedures 30 
in primary healthcare practice. To help translate the knowledge of epigenetics to public health 31 
practice the present study aims to explore the parallelism of methylation levels between white 32 
blood cells and buccal samples in relation to obesity and associated disorders. Blood and 33 
buccal swaps samples were collected from a subsample of the Spanish cohort of the Food4Me 34 
study. Infinium HumanMethylation450 DNA Analysis was carried out for the determination of 35 
methylation levels. Standard deviation for β-values method and concordance correlation 36 
analysis were used to select those CpG which showed best parallelism between samples. A 37 
total of 277 CpGs met the criteria and were selected for an enrichment analysis and a 38 
correlation analysis with anthropometrical and clinical parameters. From those selected CpGs, 39 
4 presented high associations with: BMI (cg01055691 in GAP43; r=-0.92 & rho=-0.84 for blood; 40 
r=-0.89 & rho=-0.83 for buccal sample); HOMA-IR (cg00095677 in ATP2A3; r=0.82 & rho=-0.84 41 
for blood; r=-0.8 & rho=-0.83 for buccal sample); and leptin (cg14464133 in ADARB2; r=-0.9182 42 
& rho=-0.94 for blood; r=-0.893 & rho=-0.79 for buccal sample). These findings demonstrate 43 
the potential application of non-invasive buccal samples in the identification of surrogate 44 
epigenetic biomarkers, and identify methylation sites in GAP43, ATP2A3 and ADARB2 genes as 45 
potential targets in relation to overweight management and insulin sensibility. 46 
Keywords: Methylation, obesity, parallelism, mirror tissues, surrogate tissues 47 
Introduction 48 
Obesity prevalence rates increase each year worldwide, resulting in a concomitant rise of 49 
associated metabolic diseases [13]. There are many possible causes, including the 50 
westernization of the dietary patterns, characterized by an increment of energy-dense food 51 
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consumption, as well as the wider adoption of sedentary lifestyles, which induce a chronic 52 
energy misbalance [48]. Epigenetics appear to be an important dynamic element in the 53 
adaptation to environmental changes and in the triggering of specific physiological responses 54 
[9].  55 
Several studies have shown that the epigenome has the potential to be modified by exposure 56 
to a range of nutritional factors [34]. A study by van Dijk et al, [15] has demonstrated that 57 
these epigenetic modifications are associated with a increase risk of developing obesity, as 58 
well as other non-communicable diseases such as type 2 diabetes, hypertension, 59 
dyslipidaemias or cardiovascular events [12, 16, 35, 43]. Indeed, epigenetic markers, and more 60 
specifically DNA methylation levels, may represent a potential marker for disease, which have 61 
been studied to identify a predictive role of methylation changes in pathways related to 62 
metabolic diseases [34]. Because DNA methylation patterns can be cell-type specific, these 63 
studies have investigated changes within specific cell types and tissues, such as white adipose 64 
tissue, muscle, pancreas and blood [1, 3, 14, 38, 44, 45, 54], where the functional effect is 65 
assumed to occur [32]. However, in some cases the sampling procedures are invasive and it is 66 
not possible to carry out these procedures in primary healthcare practice. For these reasons, 67 
and in order to translate the knowledge about epigenetics to public health practice and 68 
policies, there is the need to evaluate other tissues [5]. This strategy would facilitate the use of 69 
alternative and more feasible techniques from non-invasive tissues, which may “mirror” 70 
pattern of epigenetic markers in other specific tissues of interest (i.e., skeletal muscle, liver, 71 
adipose tissue, etc). To achieve this goal, research has evaluated the epigenetic modifications 72 
of obesity in less invasive and more commonly collected tissues, such as peripheral blood 73 
mononuclear cells [8, 20, 33, 53, 56]. Most recently, other studies have analysed DNA 74 
methylation patterns in peripheral tissues, blood and subcutaneous adipose tissue, to explore 75 
the parallelism in the development of different metabolic disorders related to obesity [24, 45]. 76 
Indeed, epigenetic markers in DNA from buccal swabs have been used to characterize novel 77 
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biomarkers in non-invasive, easily accessible samples. Moreover, buccal samples have been 78 
suggested as better informative surrogates than blood for epigenome-wide association studies 79 
[27]. 80 
The development of high-throughput technologies has also facilitated the analysis of different 81 
tissues to compare changes at an epigenomic level, which may have been produced by, or are 82 
associated with, metabolic diseases. These methodologies could be used to develop a  83 
“personalised nutrition” approach to provide a tailored assessment for the prevention of non-84 
communicable diseases, as well as for designing new treatments [6].  85 
Taking into account these premises, we propose to examine the eventual parallelism in DNA 86 
methylation levels between white blood cells (WBC) and buccal samples, at specific CpGs 87 
concerning obesity and associated disorders. 88 
 89 
Material and methods 90 
Study subjects 91 
A subset of volunteers were selected from the Spanish cohort of the Food4Me study, which is 92 
a randomized, longitudinal, multicentre trial of personalised nutrition advice, delivered 93 
through online assessment with four levels of intervention and two intensities [10]. A total of 94 
43 volunteers were invited to attend the University of Navarra to validate their self-reported 95 
measures carried out during the main study. Anthropometric measurements were taken by 96 
trained researchers. Blood samples were also collected after a 10-12 hours overnight fast to 97 
perform the biochemical determinations and validate the genetic data. From those 43 98 
volunteers a subsample of 10 volunteers were selected to take part in the present study. For 99 
this purpose, buccal swaps samples were collected to isolate DNA and to determine DNA 100 
methylation levels. 101 
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Procedures 102 
Anthropometric measurements: Height (cm) was measured with a calibrated stadiometer 103 
(SECA 220 Hamburg, Germany) to the nearest 0.1 cm. Body weight (kg) and body composition 104 
were assessed by Bioelectric Impedance Analysis (Tanita BC 418, TANITA Corp, Tokyo, Japan) 105 
to the nearest 0.1 kg for both. Anthropometric measurements of waist, hip and upper leg 106 
circumference (cm) were also recorded by trained staff with a commercial inelastic and flexible 107 
tape to the nearest 0.1 cm. Global adiposity was estimated by body mass index (BMI; kg/m2) 108 
and percentage of fat mass. Waist-hip ratio was calculated to assess central adiposity. 109 
Biochemical analyses: Plasma, serum and WBC were separated from whole blood samples by 110 
centrifugation, 10 minutes at 1500g at room temperature, and immediately frozen at -80°C 111 
until assay. Serum concentrations of glucose, total and HDL cholesterol, triglycerides, alanine 112 
aminotransferase (ALT), aspartate aminotransferase (AST), and homocysteine were measured 113 
by standardized methods in a Pentra C-200 autoanalyser (HORIBA ABX, Madrid, Spain): Insulin, 114 
C reactive protein (CRP), cortisol and leptin concentrations were determined by enzyme-linked 115 
immunosorbent assay (ELISA) in a Triturus autoanalyser (Grifols SA, Barcelona, Spain). Low-116 
density lipoprotein (LDL) cholesterol and Homeostasis Model Assessment Index (HOMA-IR) 117 
data were calculated according to previous described formulae [19, 29]. 118 
DNA Isolation from different tissues: DNA isolation from WBC was performed by using Master-119 
Pure DNA Purification Kit for Blood Version II (Epicenter, Madison, Wis., USA) following the 120 
manufacturer’s protocols. DNA from buccal swaps was isolated with Maxwell 16 Buccal Swab 121 
LEV DNAPurification Kit (Promega, Madison, WI, USA) following the manufacturer’s 122 
instructions. DNA concentration and purity were assessed using Nanodrop ND-1000 123 
spectrophotometer (NanoDrop Technologies, Wilmington, Germany). DNA was stored at −80 124 
°C until further analyses. 125 
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Profiling of DNA methylation levels: Methylation analyses of DNA samples were carried out 126 
using Infinium HumanMethylation450 DNA Analysis BeadChip (Illumina), with coverage of 127 
more than 480,000 methylation sites. DNA samples were bisulfite-treated using the EZ DNA 128 
Methylation kit (Zymo Research Corp, Irvine, CA, USA), and analysed according to the standard 129 
protocol for Illumina 450k microarrays, by the Genotyping and Genetic Diagnosis Unit from the 130 
University of Valencia, Spain. 131 
Statistics and data analyses 132 
Data extraction: DNA methylation signals from scanned arrays were preprocessed and 133 
normalized using the R scripts [21] of Touleimat et al. [50]. After data normalization with the 134 
DASEN method [41], a multidimensional scaling (MDS) was carried out to define the source of 135 
variation from the pooled β-values of the methylation levels of the samples.  136 
Selection of CpG sites: CpG selection was performed using the “Standard Deviation for β-137 
values” method, which has been shown to be a robust non-specific procedure in the selection 138 
of CpG and in the dimension reduction procedure performed in high-throughput databases, 139 
prior to cluster analysis [57]. According to this premise, those CpGs with higher standard 140 
deviations were chosen, assuming that those CpGs could be expected to have more biological 141 
relevance and variability. In addition a concordance correlation analysis [26] was carried out to 142 
measure the agreement between DNA methylation levels in blood and buccal swabs. This 143 
method is based on a coefficient correction that rewards the linear fit with origin in 0 and a 144 
slope with value 1. This analysis is widely used in the validation of different techniques, giving 145 
higher coefficients to those techniques presenting best accuracy and precision, with 1 being 146 
the value for perfect fit between measurements. The correlation matrix of these selected CpG 147 
was plotted in a heatmap, after unsupervised linkage clustering using Euclidean distances, to 148 
visualise the methylation patterns of those CpG with better fit between tissues. 149 
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Correlation with phenotypical characteristics: Pairwise Pearson and Spearman correlation 150 
coefficients between CpGs of both tissues and phenotypical characteristics were estimated to 151 
determine the relationship between methylation levels with anthropometrical and 152 
biochemical variables. Those CpGs that show association with any phenotypical variable and 153 
passed a p-value threshold of 0.01 (which correspond with the minimum common p-value 154 
possible for both tissues and tests) in both tissues for Pearson and Spearman tests, were 155 
selected for further investigation (Supplementary Figure 1). 156 
The Shapiro-Wilk normality test was used to determine the distribution of phenotypic 157 
variables. Accordingly, Student t-test or Mann-Whitney U test were used for parametric and 158 
nonparametric continuous variables, respectively. R-Studio software was used to carry out all 159 
the analysis and graphics. 160 
Pathway analysis 161 
The Ingenuity Pathway Analysis (IPA) (IPA software, Ingenuity Systems; Qiagen; Redwood City, 162 
CA, USA) system was used to analyse functions potentially involved in obesity or non-163 
communicable metabolic disorders. Pathway analysis was conducted on the list of genes from 164 
selected CpGs with best fitting in methylation level between tissues, to determine those 165 
pathways or functions that could be equally modified in both tissues. Each gene from the list 166 
was classified by IPA, according to pathways and functions. Fisher’s exact test was used to 167 
estimate the likelihood and the p-value of those genes participating in each pathway.  168 
Ethics 169 
The present investigation was approved by the Research Ethics Committee of the University of 170 
Navarra (ref. 041/2012). The protocol and all the procedures used during this trial are in 171 
agreement with the Helsinki Declaration articles, and European and National guidelines for 172 
Good Clinical Practices. 173 
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 174 
Results 175 
General characteristics: The sample (n=10) was composed of 6 females and 4 males, with a 176 
mean age of 36±5 years, and a BMI of 24.2±3.7 kg/m2. When the sample was dichotomised 177 
into those participants who were normal weight or overweight, defined by the BMI (Table 1), 178 
statistically significant differences were found in leptin (6.57±5.93 mg/dl vs. 16.68±8.25 mg/dl, 179 
respectively) and triglycerides (47.25±9.07 mg/dl vs. 85.67±25.75 mg/dl, respectively). 180 
Identification of concordant CpG sites: Methylation levels of all CpGs sites were plotted (Figure 181 
1a) to illustrate the concordance in methylation between both tissues. Those CpGs with 182 
stronger correlations appear on, or close to, the diagonal line, while those that are more 183 
distant from the diagonal region are more discordant. Subsequently, multidimensional scaling 184 
(MDS) analysis was carried out to confirm the presence of different methylation patterns for 185 
each tissue; the graphical representation for the two main dimensions showed the tissue 186 
grouping (Figure 1b).  187 
According to the designated criteria for the CpG selection, the standard deviations for each 188 
tissue were plotted to determine the β-value range for the collection (Figure 1c and 1d). Those 189 
CpGs with a standard deviation higher than 0.2, in at least one of the tissues, were used for 190 
subsequent analyses. In order to prevent discordances between tissues, concordance 191 
correlation analysis was carried out. The CpGs with higher concordance coefficient (higher 192 
than 0.9) were those which best fitted the diagonal line correlation between tissues. Finally, a 193 
total of 277 CpGs met both criteria and were selected for further analysis (Sup. Table 1). The 194 
hierarchical cluster analysis of those selected CpGs (Figure 2) exhibited a robust mirroring 195 
between tissues in each volunteer, showing similarities in methylation levels (expressed by the 196 
colour range) between the paired samples for each volunteer. 197 
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Enrichment analysis: Enrichment analysis was undertaken to examine the biological 198 
significance of those selected CpGs with higher parallelism between tissues, and to identify 199 
pathways or functions associated with obesity and related disorders. After the enrichment 200 
analysis with Ingenuity software, the biological pathways statistically significant containing the 201 
genes of the selected CpGs, in relationship with metabolic disease linked with obesity, were 202 
examined (Table 2). The main metabolic pathways identified by this were those related to 203 
glucose metabolism (glucose metabolism disorder, 26 molecules and p=0.001; diabetes 204 
mellitus, 22 molecules and p=0.002; carbohydrate storage, 14 molecules and p=0.002). 205 
Furthermore, pathways related to obesity (11 molecules and p=0.007) and to lipid 206 
peroxidation (5 molecules and p=0.004) were identified. 207 
Correlation analyses with phenotypic characteristics: Correlation analyses were run between 208 
the selected CpGs and the phenotypic data. Some CpGs had high correlation with BMI, HOMA-209 
IR and leptin with a p-value for Pearson and Spearman correlation test less than 0.01 in both 210 
tissues (Figure 3). These include: cg01055691 in GAP43 with BMI (r=-0.92 & rho=-0.84 for 211 
blood; r=-0.89 & rho=-0.83 for buccal sample); cg00095677 in ATP2A3 with HOMA-IR (r=0.82 & 212 
rho=-0.84 for blood; r=-0.8 & rho=-0.83 for buccal sample); and cg14464133 in ADARB2 with 213 
leptin (r=-0.9182 & rho=-0.94 for blood; r=-0.893 & rho=-0.79 for buccal sample). A 214 
complementary analysis was carried out with all the CpGs included in the three selected genes 215 
which presented association with the traits. Only two additional CpGs showed correlation 216 
between phenotypical variables when the p-value threshold was reduced to 0.05 for both tests 217 
and tissues (cg20473595 in ATP2A3 for HOMA index and cg16957758 in ADARB2 for leptin 218 
levels) 219 
Discussion 220 
In agreement with previous studies, the current investigation identified specific CpG sites 221 
which showed similar methylation patterns in both tissues and which were related to obesity 222 
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and metabolic functions, as corroborated with the enrichment software IPA [23]. Methylation 223 
of the gene GAP43 (Growth Associated Protein 43) was inversely correlated with BMI. The 224 
protein encoded by GAP43 is involved in neuronal regeneration and plasticity, but studies in 225 
rats have shown that obesity or diabetes can affect its expression [4, 52]. We observed a 226 
statistically significant correlation between circulating leptin levels and methylation of a CpG 227 
located in double-stranded RNA-specific editase B2 (ADARB2) gene which is associated with 228 
longevity in humans [40, 46]. Polymorphisms in ADARB2 are associated with higher abdominal 229 
circumference, BMI and triglyceride levels [40], but also with lower adiponectin concentration 230 
[39, 40]. Accordingly, Oguro et al proposed that changes in ADARB2 expression in the thalamus 231 
and amygdala could trigger changes in feeding behavior that promote visceral fat 232 
accumulation [40]. Finally, a correlation between the HOMA index and the methylation levels 233 
of a CpG site located in the gene body of ATP2A3 was found. This gene encodes for one of the 234 
SERCA Ca(2+)-ATPases that has been described to be involved in calcium homeostasis in 235 
pancreatic cells [51]. Also, methylation changes in CpGs of this gene have been recently 236 
described to be associated with changes in insulin in muscle samples from non-diabetic 237 
subjects. [36]. Furthermore, changes in the expression of ATP2A3 isoforms has been also 238 
related with endoplasmic reticulum stress and changes in cell adhesion capacity [11].   239 
Some studies suggest the feasibility of using epigenetic markers as an early biomarker of 240 
increased risk of specific diseases [6, 15]. Given the worldwide increase in prevalence of 241 
obesity and of obesity-related complex disorders, such as impaired glucose homeostasis, 242 
dyslipidaemias, or hypertension, which are modulated by both genetic and environmental 243 
factors, further research on early biomarkers may help to monitor and screen for the onset 244 
and progress for these diseases [7].  245 
In response to those demands, some studies are already linking epigenetic marks and obesity 246 
[2, 12, 16, 34, 43]. However, the routine collection of appropriate samples from specific tissues 247 
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for determining the developmental status of these disorders, may be a difficult task in normal 248 
clinical practice [5]. For these reasons, there is a need to identify alternative, non-invasive 249 
sample sources on which accurately reflect related methylation marks. When such tissues have 250 
been identified and validated, this biomarker approach may be applied in screening and 251 
monitoring of obesity-related disorders. Consequently, the determination of epigenetic marks 252 
that are modified in other non-specific tissues provides the opportunity of delivering 253 
personalised procedures in clinical practice [47]. Indeed, some authors have proposed the idea 254 
of using these epigenetics marks as a screening tool, to predict the risk of future disease [17, 255 
22]. For the application of these biomarkers in the clinical practice, it would be convenient that 256 
they are obtained from non-invasive procedures (such as buccal swabs), if it is confirmed that 257 
these mirror the epigenetic markers in the target tissues. In this context, differences in 258 
methylation patterns between tissues need to be further investigated [28, 32]. 259 
The development of studies that provide evidence to support the use of epigenetic marks in 260 
specific tissues as a surrogate of epigenetic status in non-invasive tissues will improve the 261 
efficiency of clinical practice [5]. In this aspect, it is also necessary to find tissues with enough 262 
cell type homogeneity in order to diminish the effects of confounding changes that could be 263 
occurring in tissues such as blood, where the health or diseases status can alter the proportion 264 
of white cells present, which may hamper the comprehension of epigenetic marks [31, 49]. For 265 
this reasons, our study provides support for the idea that methylation of DNA obtained from 266 
buccal cells may be used to identify new markers related to metabolic disorders in a 267 
homogenous cell type sample. Findings from the present study also allow identification of 268 
alterations in the digestive tract, facilitating investigation of impairments in digestion, 269 
absorption and different related disorders, such as inflammatory intestinal disorders [30, 58]. 270 
At the same time, some studies have revealed the stability of epigenetic marks over time [17]. 271 
Although some studies have reported discordance in DNA methylation results when comparing 272 
two accessible human tissues such as peripheral blood mononuclear cells and buccal epithelial 273 
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cells [25], other trials have suggested that, for epigenetic population studies, buccal swabs are 274 
likely to be a more informative surrogate tissue than blood [27]. In the same way, it is very 275 
important to take into account other possible habits that could affect the methylation levels in 276 
this surrogated tissues, such as smoking behaviour, which has been shown to be associated 277 
with changes in specific methylation sites, in buccal mucosa samples used as a surrogate 278 
tissue, that were previously associated with changes in expression of genes related with 279 
smoking –related lung diseases [55].  280 
Our findings add to the evidence from other recent studies that aimed to associate epigenetic 281 
marks in different tissues with metabolic disorders. For example, Ronn et al [45] tried to 282 
determine the effects of age, BMI, and glucose status on DNA methylation and RNA expression 283 
levels in adipose tissue and peripheral blood samples. These authors also used a wide coverage 284 
array to analyse the methylation levels, and they found a large number of genes whose 285 
methylation levels correlated with BMI and HbA1 levels in both tissues. In contrast, other 286 
recent epigenome-wide profilings of methylation levels have described different genes that 287 
could act as mirror markers in paired blood and adipose tissue samples [24]. However, the 288 
authors reported lack of association between DNA methylation levels in blood and weight 289 
status, suggesting that blood markers do not mirror adipose tissue markers [24]. Using both 290 
blood and buccal samples, Talens et al investigated the relationship between DNA methylation 291 
levels and obesity, and proposed that the study of complex disorders could be feasible with 292 
well-designed studies [49]. Other researches have used buccal samples in the search for 293 
methylation signatures in childhood psychotic symptoms [18], the response to prenatal 294 
exposure of maternal cigarette smoking [37] or the symptoms observed in children with fetal 295 
alcohol spectrum disorder [42]. 296 
The present work proposes the use of surrogate methylation markers in buccal swab samples 297 
in relation to obesity, to provide a more accessible tissue than peripheral blood cells to 298 
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perform future analyses in clinical practice, with the benefit of no need of venous puncture 299 
and the feasibility of storage of the sample before the extraction. The main limitation of the 300 
present work is the small number of volunteers, but the wide coverage of the methylation 301 
analysis and the selection methods performed are strengths. For these reasons, this study 302 
provides the bases for the future development of DNA methylation analyses in buccal swab 303 
samples as possible surrogate markers for investigation in obesity and related comorbidities. 304 
These findings show the potential application of a non-invasive approach in the identification 305 
of surrogate epigenetic biomarkers. Particularly, this study opens the door to further analysis 306 
of the roles of GAP43, ATP2A3 and ADARB2 in relation to weight management. 307 
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Tables and Figures 486 
Table 1: Anthropometric and clinical characteristics of the study population and comparison 487 
by weight status. 488 
  All Normal weight Overweight ρ 
n (female) 10 (6) 4 (3) 6 (3)  
Age (years) 36.1 ± 4.7 35.0 ± 6.1 36.8 ± 4.0 0.453 
BMI (kg/m
2
) 24.19 ± 3.67 20.72 ± 0.87 26.51 ± 2.76 0.011 
Fat mass (%) 26.39 ± 8.70 20.58 ± 9.70 30.27 ± 5.88 0.136 
Total Cholesterol (mg/dl) 193.9 ± 47.9 168.7 ± 25.2 210.67 ± 53.9 0.201 
HDL-Cholesterol (mg/dl) 58.2 ± 12.2 61.5 ± 4.9 56.0 ± 15.5 0.201 
LDL-Cholesterol (mg/dl) 121.6 ± 40.3 97.8 ± 22.1 137.5 ± 43.4 0.201 
Triglycerides (mg/dl) 70.3 ± 28.1 47.2 ± 9.1 85.7 ± 25.7 0.011 
Glucose (mg/dl) 85.3 ± 4.5 83.8 ± 4.2 86.3 ± 4.8 0.670 
Insulin (mU/l) 5.36 ± 3.52 3.84 ± 2.45 6.38 ± 3.95 0.286 
HOMA-IR 1.14 ± 0.75 0.81 ± 0.55 1.36 ± 0.83 0.286 
ALT (U/l) 25.05 ± 13.37 21.48 ± 7.27 27.43 ± 16.52 0.670 
AST (U/l) 20.97 ± 6.40 20.88 ± 7.05 21.03 ± 6.62 0.521 
Homocysteine (µmol/l) 10.64 ± 4.40 11.00 ± 3.12 10.40 ± 5.37 0.593 
C-reactive protein (µg/ml) 1.45 ± 1.37 0.54 ± 0.60 2.06 ± 1.43 0.136 
Cortisol (ng/ml) 164.1 ± 38.1 158.5 ± 31.0 167.9 ± 44.7 0.670 
Leptin (ng/ml) 12.64 ± 8.77 6.57 ± 5.93 16.68 ± 8.25 0.033 
Values expressed in mean ± standard deviation 
 489 
  490 
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Figure 1: 491 
 492 
 493 
 494 
Figure 1. Methylation characteristics by samples: a) Scatter plot of mean methylation levels of >423,000 methylation sites from 495 
blood and buccal samples; b) the first two components from MDS analysis carried out from pooled samples; c) histogram of 496 
standard deviation distribution of blood samples; and d) histogram of standard deviation distribution of buccal samples. 497 
  498 
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Figure 2: 499 
 500 
Figure 2. Heatmap of selected CpGs: Hierarchical cluster analysis of methylation levels in pooled samples showing the parallelism 501 
in methylation levels between blood and buccal samples of each volunteer in selected CpGs with standard deviation higher than 502 
0.2 and concordance coefficient higher than 0.9. Similarities in the colours of paired samples for each volunteer show the 503 
analogous methylation levels for the selected CpG in both tissues, confirming visually the results obtained from concordance 504 
analysis. 505 
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Table 2: Annotated functions of the genes whose methylation levels showed higher parallelism between tissues, according to the enrichment analysis by 
Ingenuity of selected CpGs with standard deviation higher than 0.2 and concordance coefficient higher than 0.9. 
Category Function Annotation p-value Genes 
Number of 
genes 
Metabolic Disease 
glucose metabolism 
disorder 
0.00108 
COL6A1, DIP2C, FASN, GAA, GABRP, GCK, GNAS, 
HDAC4, HK2, HLA-C, HLA-DQA1, HLA-DQB1, HTR4, 
HTT, ITGB2, MAGI2, PASK, PDE2A, PTGER3, RNF39, 
SAMD4A, SCN1A, SLC25A13, TNXB, TRIM26, UBE2E3 
26 
Endocrine System 
Disorders 
diabetes mellitus 0.00168 
COL6A1, DIP2C, FASN, GAA, GABRP, GCK, HK2, HLA-
C, HLA-DQA1, HLA-DQB1, HTR4, HTT, ITGB2, MAGI2, 
PDE2A, PTGER3, RNF39, SAMD4A, SCN1A, TNXB, 
TRIM26, UBE2E3 
22 
Carbohydrate 
Metabolism 
quantity of carbohydrate 
storage 
0.0021 
FASN, FSTL1, GAA, GCK, GNAS, HDAC4, HK2, HTT, 
ITGB2, LGALS8, MGAT5B, PCCA, SLC25A13, XYLT1 
14 
Nutritional Disease obesity 0.00738 
FASN, GABRP, GCK, GNAS, GNRHR, HTR4, PASK, 
PTGER3, SAMD4A, SCN1A, TXNRD1 
11 
Carbohydrate 
Metabolism 
metabolism of 
polysaccharide 
0.00221 AOAH, CASR, CEMIP, GAA, GCK, PASK, SULF2, XYLT1 8 
Endocrine System 
Disorders 
diabetic complication 0.00599 COL6A1, FASN, MAGI2, PDE2A, PTGER3, SCN1A 6 
Carbohydrate 
Metabolism 
quantity of glycogen 
storage 
0.00019 FSTL1, GAA, GCK, GNAS, HK2, PCCA 6 
Lipid Metabolism peroxidation of lipid 0.00374 AATF, HTT, MAPT, PTGER3, SH3BP5 5 
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Figure 3: 
 
 
Figure 3: Associations between the methylation levels of CpGs located in GAP43, ATP2A3 and ADARB2, in both blood and 
buccal samples with BMI, HOMA index and leptin levels respectively. The scatter plots represent the methylation level of each 
CpG which present a p-value <0.01 for both tissues and by Pearson and Searman correlation test. The fitted linear line has been 
also represented. 
24 
 
Supplementary figure 1: 
 
Supplementary figure 1. Venn diagrams for CpG selection. Venn diagrams depicting 
the selection of CpGs that correlate in both tissues with significance level p<0.01 in 
Pearson and Spearman tests with the associated traits. a) Representation of the 
intersecting number of CpGs that correlates with BMI (kg/m2); the only CpG for this 
trait was cg01055691 in the GAP43 gene. b) Representation of the intersecting 
number of CpGs that correlates with HOMA index; the only CpG for this trait was 
cg00095677 in the ATP2A3 gene. Finally, c) Representation of the intersecting number 
of CpGs that correlates with leptin levels (ng/ml); the only CpG for this trait was 
cg14464133 in the ADARB2 gene. 
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Supplementary table 1: Location characteristics and concordance coefficient between tissues 
of selected CpGs with standard deviation higher than 0.2 and concordance coefficient higher 
than 0.9. 
ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg00095677 17:3833739 ATP2A3 Body Open Sea 0.989 
cg00156497 6:133663589 EYA4 Body Open Sea 0.980 
cg00211215 6:32552246 HLA-DRB1 Body Island 0.960 
cg00247094 17:77922972 TBC1D16 Body Island 0.957 
cg00256329 17:724374 NXN Body Open Sea 0.990 
cg00443543 17:1645410 SERPINF2 TSS1500 Open Sea 0.986 
cg00540295 9:139616839 FAM69B Body N_Shore 0.979 
cg00881894 2:166930521 SCN1A TSS1500 Open Sea 0.950 
cg00939438 14:55151579 SAMD4A Body Open Sea 0.981 
cg01012836 12:125810767 TMEM132B TSS1500 Open Sea 0.915 
cg01055691 3:115376349 GAP43 Body N_Shore 0.927 
cg01081438 1:92417998 BRDT 5UTR S_Shelf 0.993 
cg01128042 10:115465924 CASP7 Body Open Sea 0.959 
cg01296877 1:2274955 MORN1 Body N_Shore 0.971 
cg01502466 6:29898751 
 
Intergenic S_Shelf 0.975 
cg01550813 7:134427910 
 
Intergenic Open Sea 0.990 
cg01584086 11:10373718 
 
Intergenic Open Sea 0.949 
cg01647917 19:542653 GZMM TSS1500 S_Shore 0.979 
cg01808284 5:148031958 HTR4 5UTR N_Shore 0.969 
cg01821635 1:101089253 
 
Intergenic Open Sea 0.945 
cg01835922 11:121626930 
 
Intergenic Open Sea 0.979 
cg01941243 1:227971215 
 
Intergenic N_Shelf 0.982 
cg02093708 16:87577273 
 
Intergenic Open Sea 0.992 
cg02100397 19:646890 
 
Intergenic Island 0.964 
cg02113055 10:45072520 
 
Intergenic Open Sea 0.985 
cg02239586 20:62678536 
 
Intergenic N_Shore 0.960 
cg02299007 8:1140574 
 
Intergenic S_Shore 0.957 
cg02353427 2:25079600 ADCY3 Body Open Sea 0.985 
cg02372404 10:131209556 
 
Intergenic Open Sea 0.985 
cg02464073 21:46349496 ITGB2 TSS1500 N_Shore 0.987 
cg02533724 10:130279912 
 
Intergenic Open Sea 0.927 
cg02668233 12:125813494 TMEM132B Body N_Shelf 0.993 
cg02722613 4:25162898 SEPSECS TSS1500 S_Shore 0.987 
cg02749948 6:32073700 TNXB 5UTR Open Sea 0.989 
cg02890235 19:55735946 
 
Intergenic Open Sea 0.925 
cg02940070 22:43343608 PACSIN2 TSS1500 Open Sea 0.926 
cg03028786 2:224897425 SERPINE2 5UTR Open Sea 0.976 
cg03075889 7:1976457 MAD1L1 Body Island 0.991 
cg03084184 10:133981681 JAKMIP3 3UTR Open Sea 0.946 
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ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg03115532 6:28185726 LOC222699 Body N_Shore 0.985 
cg03129555 1:198466250 
 
Intergenic Open Sea 0.994 
cg03136151 1:92415048 BRDT 5UTR S_Shore 0.974 
cg03216697 6:31239295 HLA-C Body Island 0.974 
cg03329597 3:108125523 MYH15 Body Open Sea 0.937 
cg03407524 17:80043349 FASN Body S_Shore 0.978 
cg03466780 9:140247365 EXD3 Body N_Shore 0.994 
cg03570263 6:30040291 RNF39 Body S_Shore 0.994 
cg03704393 9:97042001 ZNF169 Body Open Sea 0.995 
cg03812172 7:44184403 GCK 3UTR N_Shore 0.968 
cg04003990 2:242056286 PASK Body Open Sea 0.946 
cg04012354 4:143771325 
 
Intergenic S_Shelf 0.989 
cg04073914 4:84461507 AGPAT9 Body S_Shelf 0.996 
cg04090468 7:156181990 
 
Intergenic Open Sea 0.965 
cg04131969 2:33951647 MYADML Body N_Shore 0.993 
cg04246708 1:246785611 CNST Body S_Shore 0.988 
cg04388792 19:12707977 ZNF490 Body Island 0.992 
cg04546413 19:29218101 
 
Intergenic Island 0.986 
cg04875706 15:97311928 
 
Intergenic Open Sea 0.925 
cg04998327 11:103453960 
 
Intergenic Open Sea 0.985 
cg05023192 2:240965916 NDUFA10 TSS1500 S_Shore 0.982 
cg05084668 3:125655381 ALG1L 5UTR Open Sea 0.933 
cg05134736 12:378771 
 
Intergenic Open Sea 0.931 
cg05161773 17:75378036 sep-09 5UTR Open Sea 0.983 
cg05291429 17:1494566 SLC43A2 Body S_Shelf 0.990 
cg05308244 12:130968528 RIMBP2 5UTR Open Sea 0.954 
cg05331763 17:80535367 FOXK2 Body S_Shore 0.988 
cg05392448 1:2266933 MORN1 Body S_Shore 0.928 
cg05407200 11:93586725 
 
Intergenic S_Shelf 0.961 
cg05528899 17:57120 
 
Intergenic Island 0.983 
cg05593887 7:77827379 MAGI2 Body Open Sea 0.961 
cg05656210 5:141660565 
 
Intergenic Open Sea 0.950 
cg05708441 2:132186821 
 
Intergenic S_Shelf 0.989 
cg05813498 17:78093353 GAA 3UTR Open Sea 0.993 
cg05867245 20:62402415 ZBTB46 Body Island 0.984 
cg05995465 2:240313602 HDAC4 5UTR Open Sea 0.983 
cg06032337 6:29648468 
 
Intergenic Open Sea 0.962 
cg06051619 10:593275 DIP2C Body Open Sea 0.984 
cg06378561 3:120151283 FSTL1 Body Open Sea 0.997 
cg06621919 1:208309239 PLXNA2 Body Open Sea 0.972 
cg06684911 19:1792217 ATP8B3 Body N_Shelf 0.965 
cg06894070 11:71238205 KRTAP5-7 TSS200 Open Sea 0.981 
cg06899226 15:36524258 
 
Intergenic Open Sea 0.958 
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ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg06960717 7:64894780 
 
Intergenic Open Sea 0.991 
cg07456585 14:74704714 VSX2 TSS1500 N_Shore 0.972 
cg07844442 10:129144269 DOCK1 Body Open Sea 0.971 
cg07909498 4:79627477 
 
Intergenic Open Sea 0.950 
cg08084984 16:17482912 XYLT1 Body Open Sea 0.978 
cg08146865 3:48335857 NME6 3UTR Open Sea 0.984 
cg08210706 14:95046686 SERPINA5 TSS1500 Open Sea 0.950 
cg08238319 5:404713 AHRR Body Open Sea 0.962 
cg08266644 1:214317404 
 
Intergenic Open Sea 0.990 
cg08292959 17:74878420 MGAT5B Body Island 0.989 
cg08429705 19:2583601 GNG7 5UTR S_Shelf 0.977 
cg08477332 1:153590243 S100A14 TSS1500 Open Sea 0.976 
cg08551408 2:2732624 
 
Intergenic Open Sea 0.928 
cg08717807 16:85531414 
 
Intergenic S_Shore 0.980 
cg08896901 4:152996165 
 
Intergenic Open Sea 0.947 
cg08916385 4:68622534 GNRHR TSS1500 Open Sea 0.928 
cg09015880 17:47207658 
 
Intergenic N_Shelf 0.981 
cg09175792 10:50534598 C10orf71 Body Island 0.939 
cg09281805 7:4751840 FOXK1 Body Open Sea 0.987 
cg09284209 12:124585152 
 
Intergenic Open Sea 0.924 
cg09352518 19:21265421 ZNF714 5UTR Island 0.949 
cg09411910 6:32607224 HLA-DQA1 Body Open Sea 0.913 
cg09438069 4:187581093 FAT1 Body Open Sea 0.981 
cg09518270 1:211308115 KCNH1 TSS1500 S_Shore 0.962 
cg09627057 3:15377670 SH3BP5 5UTR S_Shelf 0.995 
cg09866143 3:124861521 SLC12A8 Body S_Shore 0.989 
cg09885502 20:57463991 GNAS 3UTR Island 0.971 
cg10155537 1:248512094 OR14C36 1stExon Open Sea 0.952 
cg10317314 12:31272114 
 
Intergenic Open Sea 0.944 
cg10410513 8:1893887 ARHGEF10 Body Island 0.986 
cg10415021 11:110890228 
 
Intergenic Open Sea 0.973 
cg10526376 2:1788254 
 
Intergenic Open Sea 0.979 
cg10596483 8:143751796 JRK TSS1500 S_Shore 0.922 
cg10610477 2:60712421 BCL11A Body Open Sea 0.978 
cg10632770 15:81122346 KIAA1199 5UTR Open Sea 0.981 
cg10701801 1:52082593 OSBPL9 TSS200 Open Sea 0.941 
cg10760240 17:35414006 AATF 3UTR Open Sea 0.992 
cg10788927 21:47419697 COL6A1 Body N_Shore 0.970 
cg10900271 7:156157852 
 
Intergenic Open Sea 0.987 
cg10909185 11:75139736 KLHL35 Body Island 0.914 
cg10985055 6:30174131 TRIM26 5UTR Open Sea 0.968 
cg10995422 6:32522872 HLA-DRB6 Body Open Sea 0.979 
cg11010744 7:171613 
 
Intergenic Open Sea 0.972 
28 
 
ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg11418303 1:71511514 PTGER3 Body N_Shore 0.951 
cg11424828 8:2075469 MYOM2 Body Island 0.913 
cg11477175 10:114604922 
 
Intergenic Open Sea 0.967 
cg11663691 4:119759900 
 
Intergenic S_Shelf 0.982 
cg11716267 2:24367828 LOC375190 Body Open Sea 0.975 
cg11738485 19:12877000 HOOK2 Body Island 0.975 
e 10:134800741 
 
Intergenic N_Shelf 0.903 
cg11866463 21:35982790 RCAN1 5UTR N_Shelf 0.970 
cg11888470 6:32526021 HLA-DRB6 Body Open Sea 0.980 
cg12036633 15:63758958 
 
Intergenic Open Sea 0.961 
cg12169700 7:1923695 MAD1L1 Body Open Sea 0.983 
cg12381531 3:8881526 
 
Intergenic Open Sea 0.959 
e 20:62098002 KCNQ2 Body Island 0.961 
cg12421087 10:1083304 C10orf110 Body Open Sea 0.976 
cg12434901 17:61602292 KCNH6 Body Open Sea 0.978 
cg12459000 1:21032072 KIF17 Body S_Shore 0.921 
cg12657416 9:139607421 FAM69B Body Island 0.958 
cg13127920 12:124810173 NCOR2 Body N_Shore 0.974 
cg13160627 7:211932 FAM20C Body Open Sea 0.989 
cg13167158 1:1562535 MIB2 Body N_Shore 0.986 
cg13295089 7:155492281 RBM33 Body Open Sea 0.983 
cg13591052 5:97873389 
 
Intergenic Open Sea 0.965 
cg13653328 5:148520669 ABLIM3 TSS1500 N_Shore 0.972 
cg13655986 10:129197384 DOCK1 Body S_Shore 0.974 
cg13703663 7:2765455 
 
Intergenic Open Sea 0.978 
cg13748354 7:2289888 NUDT1 Body N_Shelf 0.985 
cg13824456 7:13837775 
 
Intergenic Open Sea 0.938 
e 5:172970 PLEKHG4B Body S_Shelf 0.978 
cg13972557 5:116075820 
 
Intergenic Open Sea 0.985 
cg14023020 8:1972405 
 
Intergenic Island 0.942 
cg14114910 9:124924045 MORN5 Body S_Shore 0.981 
cg14192979 17:12562530 
 
Intergenic Open Sea 0.915 
cg14195178 17:80849463 TBCD Body Open Sea 0.996 
e 4:184250312 
 
Intergenic Open Sea 0.950 
cg14252149 1:236707045 LGALS8 Body Open Sea 0.983 
cg14323910 6:32628305 HLA-DQB1 Body N_Shelf 0.948 
cg14350224 11:63885769 FLRT1 3UTR Island 0.973 
cg14464133 10:1245586 ADARB2 Body Open Sea 0.967 
cg14651435 7:157209551 DNAJB6 3UTR S_Shore 0.977 
cg14815891 20:29611903 FRG1B Body Island 0.911 
cg14883135 2:43051175 
 
Intergenic N_Shelf 0.965 
cg14893161 1:205819251 PM20D1 5UTR S_Shore 0.944 
cg15014361 6:32609212 HLA-DQA1 Body Open Sea 0.987 
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ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg15150396 2:71787431 DYSF Body Island 0.960 
cg15295200 3:139397901 NMNAT3 TSS1500 S_Shore 0.949 
cg15613905 5:112454695 MCC Body Open Sea 0.972 
cg15668967 5:1180364 
 
Intergenic Open Sea 0.988 
cg15775217 12:104676774 TXNRD1 Body N_Shelf 0.951 
cg15800276 7:154958660 
 
Intergenic Open Sea 0.988 
cg15876198 14:95106927 SERPINA13 TSS200 Open Sea 0.976 
cg15958422 2:150845309 
 
Intergenic Open Sea 0.932 
cg15988569 10:118380345 PNLIPRP2 TSS200 Open Sea 0.954 
cg16069065 7:129412730 
 
Intergenic Open Sea 0.985 
cg16081854 5:308268 AHRR Body N_Shore 0.994 
cg16112880 1:201123745 TMEM9 TSS200 Island 0.980 
cg16144436 17:7645325 DNAH2 Body S_Shore 0.979 
cg16241932 6:157876915 ZDHHC14 Body Open Sea 0.972 
cg16312212 8:18941574 
 
Intergenic Open Sea 0.985 
cg16490124 1:235292369 SNORA14B TSS1500 Island 0.995 
cg16490805 16:10281150 
 
Intergenic S_Shelf 0.981 
cg16527629 6:34524698 SPDEF TSS1500 Open Sea 0.997 
cg16542356 7:1121190 C7orf50 Body S_Shore 0.967 
cg16702660 14:22361282 
 
Intergenic Open Sea 0.981 
cg16792234 7:95828497 SLC25A13 Body Open Sea 0.940 
cg16866567 8:38759261 PLEKHA2 5UTR Island 0.979 
cg16964206 7:91795363 LOC401387 TSS1500 Open Sea 0.972 
cg17113602 20:62110277 
 
Intergenic N_Shore 0.959 
cg17149911 2:69812277 AAK1 Body Open Sea 0.956 
cg17181941 2:97004840 NCAPH Body S_Shelf 0.955 
cg17187785 11:132107476 NTM Body Open Sea 0.958 
cg17225604 17:22193895 
 
Intergenic S_Shore 0.955 
cg17329602 7:1948947 MAD1L1 Body N_Shore 0.946 
cg17343385 20:62552607 DNAJC5 5UTR S_Shore 0.988 
cg17388779 3:109537321 
 
Intergenic Open Sea 0.943 
cg17671604 19:41032399 SPTBN4 Body N_Shelf 0.984 
cg18032705 20:47253042 PREX1 Body Island 0.963 
cg18075755 4:15429967 C1QTNF7 5UTR Open Sea 0.958 
cg18239511 14:96563269 
 
Intergenic Open Sea 0.956 
cg18346634 1:29190137 OPRD1 3UTR S_Shore 0.979 
cg18827503 13:112574260 
 
Intergenic N_Shore 0.984 
cg18878992 17:43974344 MAPT 5UTR Island 0.995 
cg18938907 1:110230456 GSTM1 1stExon Island 0.942 
cg19235645 12:124787691 FAM101A 5UTR N_Shore 0.974 
cg19248407 7:101662116 CUX1 Body Open Sea 0.968 
cg19311470 4:39460490 RPL9 TSS1500 Island 0.989 
cg19353052 12:113516445 DTX1 Body S_Shore 0.991 
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ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg19360212 10:123731471 NSMCE4A Body N_Shelf 0.972 
cg19389973 7:36692197 AOAH Body Open Sea 0.990 
cg19504860 19:21512191 ZNF708 1stExon Open Sea 0.986 
cg19949776 15:51236304 LOC100132724 TSS200 Open Sea 0.961 
cg19996396 3:121946297 CASR 5UTR N_Shelf 0.976 
cg20040891 12:133007812 
 
Intergenic N_Shore 0.939 
cg20090066 11:72327160 PDE2A Body Open Sea 0.968 
cg20205188 10:1251771 ADARB2 Body N_Shore 0.987 
cg20218571 18:77678514 PQLC1 Body Island 0.993 
cg20536971 13:100989375 PCCA Body Open Sea 0.944 
cg20592836 20:33292126 TP53INP2 TSS200 Island 0.993 
cg20961245 6:29649092 
 
Intergenic Open Sea 0.920 
cg21130926 20:46415320 SULF2 TSS1500 Island 0.989 
cg21139150 21:46976175 
 
Intergenic Island 0.946 
cg21209485 1:2529359 MMEL1 Body S_Shore 0.978 
cg21294301 1:8120055 
 
Intergenic Open Sea 0.984 
cg21446655 2:181866505 UBE2E3 Body Open Sea 0.975 
cg21792493 14:104652867 
 
Intergenic Open Sea 0.918 
cg21810411 6:32549139 HLA-DRB1 Body N_Shelf 0.982 
cg21885112 7:150026567 C7orf29 TSS1500 Open Sea 0.965 
cg22274196 13:95958190 
 
Intergenic S_Shelf 0.986 
cg22274273 6:135137590 
 
Intergenic Open Sea 0.950 
cg22276800 2:75059013 HK2 TSS1500 N_Shore 0.988 
cg22336867 19:39265241 LGALS7 TSS1500 S_Shelf 0.980 
cg22901347 3:171138553 TNIK Body Open Sea 0.952 
cg22984282 6:32632568 HLA-DQB1 Body Island 0.938 
cg23187802 10:81173663 ZCCHC24 Body Open Sea 0.951 
cg23248424 5:179741104 GFPT2 Body Island 0.930 
cg23468456 3:134033339 
 
Intergenic S_Shore 0.970 
cg23489384 14:21199099 
 
Intergenic Open Sea 0.988 
cg23499373 19:58578578 ZNF135 Body Open Sea 0.960 
cg23564471 1:204951209 NFASC Body Island 0.952 
cg23691406 14:71112909 TTC9 Body S_Shelf 0.994 
cg23758822 17:41437982 
 
Intergenic N_Shore 0.990 
cg23762722 17:43817897 
 
Intergenic Open Sea 0.964 
cg23803868 19:2340235 SPPL2B Body Island 0.993 
cg23936477 18:73139742 C18orf62 TSS200 Open Sea 0.985 
cg24018148 6:39290715 KCNK16 TSS1500 Open Sea 0.970 
cg24506221 1:110230401 GSTM1 TSS200 Island 0.968 
cg24634471 8:143751801 JRK TSS1500 S_Shore 0.972 
cg24638099 6:32526027 HLA-DRB6 Body Open Sea 0.969 
cg24643105 11:113928473 
 
Intergenic N_Shore 0.989 
cg24859648 20:17680544 BANF2 TSS200 Open Sea 0.950 
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ID 
Chromosome 
and position 
Gene Relation to 
gene region 
Relation to UCSC 
CpG Island 
Concordance 
coefficient 
cg25013753 10:49654342 ARHGAP22 3UTR N_Shelf 0.969 
cg25174111 11:65631880 MUS81 Body S_Shelf 0.994 
cg25203856 11:7059980 NLRP14 Body Open Sea 0.966 
cg25593194 1:17394374 PADI2 3UTR Open Sea 0.961 
cg25674027 12:103325781 
 
Intergenic Open Sea 0.986 
cg25873514 17:81014413 
 
Intergenic N_Shore 0.984 
cg26035071 1:209982407 
 
Intergenic S_Shelf 0.979 
cg26128129 4:3235589 HTT Body Open Sea 0.991 
cg26179400 2:153355619 FMNL2 Body Open Sea 0.954 
cg26184765 4:103172826 SLC39A8 3UTR Open Sea 0.974 
cg26422465 1:3561008 WDR8 Body Island 0.995 
cg26813483 13:111980537 C13orf16 Body S_Shore 0.932 
cg26846076 17:20128997 CYTSB Body Open Sea 0.947 
cg26864661 12:76661181 
 
Intergenic Open Sea 0.923 
cg27056740 14:101507727 MIR300 Body Open Sea 0.992 
cg27086157 13:114872606 RASA3 Body N_Shelf 0.977 
cg27129755 5:170210586 GABRP TSS200 Open Sea 0.937 
cg27225663 6:169142715 
 
Intergenic Open Sea 0.983 
cg27288829 19:3771880 RAX2 5UTR S_Shore 0.968 
cg27433479 1:1687481 NADK Body S_Shore 0.991 
cg27468880 7:965995 ADAP1 Body Island 0.969 
cg27481428 7:155623690 
 
Intergenic Island 0.918 
cg27586797 5:13664584 
 
Intergenic Open Sea 0.961 
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Figure legends: 
Figure 1. Methylation characteristics by samples: a) Scatter plot of mean methylation 
levels of >423,000 methylation sites from blood and buccal samples; b) the first two 
components from MDS analysis carried out from pooled samples; c) histogram of 
standard deviation distribution of blood samples; and d) histogram of standard 
deviation distribution of buccal samples. 
Figure 2. Heatmap of selected CpGs. Hierarchical cluster analysis of methylation levels 
in pooled samples showing the parallelism in methylation levels between blood and 
buccal samples of each volunteer in selected CpGs with standard deviation higher 
than 0.2 and concordance coefficient higher than 0.9. Similarities in the colours of 
paired samples for each volunteer show the analogous methylation levels for the 
selected CpG in both tissues, confirming visually the results obtained from 
concordance analysis. 
Figure 3: Associations between the methylation levels of CpGs located in GAP43, 
ATP2A3 and ADARB2, in both blood and buccal samples, with BMI, HOMA index and 
leptin levels respectively. The scatter plots represent the methylation level of each 
CpG which present a p-value <0.01 for both tissues and by Pearson and Spearman 
correlation tests. The fitted linear line has been also represented. 
Supplementary figure 1. Venn diagrams for CpG selection. Venn diagrams depicting 
the selection of CpGs that correlate in both tissues with significance level p<0.01 in 
Pearson and Spearman tests with the associated traits. a) Representation of the 
intersecting number of CpGs that correlates with BMI (kg/m2); the only CpG for this 
trait was cg01055691 in the GAP43 gene. b) Representation of the intersecting 
number of CpGs that correlates with HOMA index; the only CpG for this trait was 
cg00095677 in the ATP2A3 gene. Finally, c) Representation of the intersecting number 
of CpGs that correlates with leptin levels (ng/ml); the only CpG for this trait was 
cg14464133 in the ADARB2 gene. 
 
